« CpG Methylation System Revealed in Western Honey Bee | Home | New Related Posts Feature »
Epigenomics To Focus On Late Stage Product Development
By Trevor | November 4, 2006
Epigenomics, the molecular diagnostic company using methylation biomarkers to develop clinical tests for the early detection of various cancers, has recently made several announcements:
- On October 26, the company announced that it would shift its focus primarily to late stage product development. “To maximize its future growth potential and to enforce financial discipline, Epigenomics will focus its product development efforts entirely on later-stage programs in oncology, which are the company’s key value drivers and greatest commercial opportunities.” The company also noted that as part of this shift in focus, it would lay off approximately one-third of its Berlin office staff. Its Seattle office would be unaffected.
- On November 2, the company reported its third quarter 2006 earnings.
- In addition, the company’s research paper chronicling the DNA methylation profile of human chromosomes 6, 20, and 22, as part of the Human Epigenome Project, was published online ahead of print at Nature Genetics.
Related Posts:
Topics: cancer, news links, research articles |
Comments are closed.
